Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.2013822237781
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Politi K, Herbst RS. EGFR mutations in non-small-cell lung cancer: find, divide, and conquer. JAMA Oncol. 2015;1(2):146–148. doi:10.1001/jamaoncol.2014.27826181013
   PubMed Web of Science ®Google Scholar
• Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54. doi:10.3978/j.issn.2218-6751.2014.05.0125806345
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.26609494
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang Y, Zhan Y, et al. Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma. Cancer Manage Res. 2019;11:6139–6150. doi:10.2147/CMAR.S200126
   PubMedGoogle Scholar
• Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. 2012;17(6):863–870. doi:10.1634/theoncologist.2011-042622581822
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi:10.1016/S1470-2045(13)70604-124439929
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi:10.1056/NEJMoa081069919692680
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• Leung L, Mok TS, Loong H. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Ther Adv Med Oncol. 2012;4(4):173–181. doi:10.1177/175883401244001522754591
   PubMed Web of Science ®Google Scholar
• Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136–142. doi:10.1016/j.lungcan.2013.06.00823910908
   PubMed Web of Science ®Google Scholar
• Costa DB, Nguyen KS, Cho BC, et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008;14(21):7060–7067. doi:10.1158/1078-0432.CCR-08-145518981003
   PubMed Web of Science ®Google Scholar
• Rukazenkov Y, Speake G, Marshall G, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs. 2009;20(10):856–866. doi:10.1097/CAD.0b013e32833034e119657272
   PubMed Web of Science ®Google Scholar
• Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203–213. doi:10.1038/clpt.2012.7322739140
   PubMed Web of Science ®Google Scholar
• Zenke Y, Yoh K, Matsumoto S, et al. Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412–418. doi:10.1016/j.cllc.2016.01.00626944770
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Sato S, Kodama T, et al. Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer. Mol Clin Oncol. 2016;4(5):873–877. doi:10.3892/mco.2016.81027123299
   PubMedGoogle Scholar
• Chen YM, Lai CH, Chang HC, et al. Antacid use and de novo brain metastases in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who were treated using first-line first-generation epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One. 2016;11(2):e0149722. doi:10.1371/journal.pone.014972226894507
   PubMed Web of Science ®Google Scholar
• Wu TY, Majeed A, Kuo KN. An overview of the healthcare system in Taiwan. London J Prim Care. 2010;3(2):115–119. doi:10.1080/17571472.2010.11493315
   PubMedGoogle Scholar
• Wang BY, Huang JY, Cheng CY, Lin CH, Ko J, Liaw YP. Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol. 2013;8(9):1128–1135. doi:10.1097/JTO.0b013e31829ceba423945383
   PubMed Web of Science ®Google Scholar
• Sharma M, Holmes HM, Mehta HB, et al. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155–1162. doi:10.1002/cncr.3191730605231
   PubMed Web of Science ®Google Scholar
• Chu MP, Ghosh S, Chambers CR, et al. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 2015;16(1):33–39. doi:10.1016/j.cllc.2014.07.00525246385
   PubMed Web of Science ®Google Scholar
• Cho S, Yee J, Kim JY, Jeong Rhie S, Gwak HS. Effects of concomitant medication use on gefitinib-induced hepatotoxicity. J Clin Pharmacol. 2018;58(2):263–268. doi:10.1002/jcph.101028981161
   PubMed Web of Science ®Google Scholar
• Rossi G, Pezzuto A, Sini C, et al. Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol. 2019;142:26–34. doi:10.1016/j.critrevonc.2019.07.00531352168
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399–405. doi:10.1007/s00280-012-1929-422806307
   PubMed Web of Science ®Google Scholar
• Deng Y, Feng W, Wu J, et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol Clin Oncol. 2014;2(1):116–120. doi:10.3892/mco.2013.19024649318
   PubMedGoogle Scholar
• Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther. 2019;12:5467–5484. doi:10.2147/OTT.S19487031371986
   PubMed Web of Science ®Google Scholar
• Vishwanathan K, Dickinson PA, Bui K, et al. The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol. 2018;58(4):474–484. doi:10.1002/jcph.103529178442
   PubMed Web of Science ®Google Scholar
• van Leeuwen RW, Peric R, Hussaarts KG, et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2016;34(12):1309–1314. doi:10.1200/JCO.2015.65.256026858332
   PubMed Web of Science ®Google Scholar